FirstIgnite is supporting the commercialization of Florida International University’s T5E based methods to identify DNA topos inhibitors technology. This technology involves precise assays for screening compound libraries to identify potential inhibitors targeting various DNA topoisomerases, including bacterial DNA topoisomerases I and II, and DNA gyrases.

This technology has significant implications for drug development, especially antibiotics and anticancer drugs. The global antibiotics market size was valued at $48.73 billion in 2022 and is expected to increase to $68.04 billion by 2030.

Florida International University’s T5E based methods to identify DNA topos inhibitors technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Florida International University team, you can schedule a time directly on their team’s calendar here.